You are viewing: Europe Recombinant Proteins Market analysis
Part of: Recombinant Proteins Market (Global)

The Europe Recombinant Proteins Market was valued at $577.9 Million in 2023 and projected to reach to $803.4 Million by 2028, representing a compound annual growth rate of 6.8%. Europe's recombinant proteins market is positioned for steady expansion through 2028, supported by increasing prevalence of chronic diseases, growing demand for biologic therapeutics, and expanding applications in oncology, immunology, and rare diseases.

Europe Recombinant Proteins Market (2023-2028) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Europe Recombinant Proteins Market Trends and Insights

  • Europe maintains a strong position in the global recombinant proteins landscape, driven by advanced biopharmaceutical infrastructure, robust regulatory frameworks, and significant investment in biotechnology research and development.
  • The region's established healthcare systems and high adoption rates of innovative therapeutic proteins support sustained market expansion through 2028. The European recombinant proteins market benefits from a concentration of leading biopharmaceutical companies, academic research institutions, and contract manufacturing organizations.
  • Europe's commitment to precision medicine and personalized therapeutics continues to fuel demand for recombinant protein-based treatments across oncology, immunology, and rare disease segments.
  • Regulatory harmonization through the European Medicines Agency (EMA) and increasing collaborations between public and private sectors further accelerate market growth in Europe during the forecast period..

Key Market Statistics

  • CAGR (2023-2028) 6.8% CAGR
  • Market Size, 2023 ~USD 577.9 Million
  • Forecast, 2028 ~USD 803.4 Million
  • Geography Europe

Europe Recombinant Proteins Market Overview

Market Valuation & Growth :

Europe's recombinant proteins market reached $577.9 million in 2023 and is forecast to grow to $803.4 million by 2028, representing a steady 6.8% CAGR, demonstrating sustained demand across the region.

Advanced Biopharmaceutical Infrastructure :

Europe benefits from world-class research institutions, manufacturing facilities, and a mature biopharmaceutical ecosystem that supports innovation and commercialization of recombinant protein therapeutics.

Robust Regulatory Framework :

The European Medicines Agency (EMA) provides stringent yet efficient regulatory pathways, ensuring high-quality recombinant protein products and fostering investor confidence in the European market.

Strong R&D Investment :

Significant biotechnology research funding and public-private partnerships across European nations drive continuous innovation in recombinant protein development and therapeutic applications.

Europe Recombinant Proteins Market Dynamics

  • The region's commitment to precision medicine and personalized healthcare further accelerates market growth. Key growth drivers include rising healthcare expenditures, aging populations requiring advanced treatments, and strengthening collaborations between academic institutions and pharmaceutical companies.
  • Europe's emphasis on sustainable manufacturing practices and biosimilar development also creates additional market opportunities, positioning the region as a critical hub for recombinant protein innovation and production..

Market Ecosystem

logo-mobile

RECOMBINANT PROTEINS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Recombinant cytokines and growth factors from its Gibco, Invitrogen, and PeproTech brands are used in cell culture, drug discovery, immunology research, stem cell expansion, and cell therapy manufacturing. Its GMP-grade proteins support the production of cell-based therapies. Supports reproducible cell culture and immune-cell expansion | Enables research-to-manufacturing workflows | Supports clinical manufacturing requirements through GMP-grade proteins.
company logo
Merck provides recombinant protein expression and process-development technologies for biopharmaceutical applications. Its CHOZN expression platform and associated process-development services support the development and scale-up of recombinant proteins and other biologics. Supports high-producing cell-line development | Facilitates process optimization and scale-up | Helps improve manufacturing productivity and consistency.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Key Takeaways

    • Europe's recombinant proteins market is valued at $577.9 million in 2023 and will reach $803.4 million by 2028, growing at a 6.8% CAGR.
    • Europe's advanced biopharmaceutical infrastructure and EMA regulatory framework position the region as a global leader in recombinant protein development and commercialization.
    • Strong demand for recombinant protein therapeutics in Europe is driven by oncology, immunology, and rare disease applications with high unmet medical needs.
    • Europe's collaborative ecosystem of pharmaceutical companies, research institutions, and contract manufacturers supports sustained innovation and market growth through 2028.

    Recombinant Proteins Market Report Scope

    Report Metric Details
    Base Year 2023
    Fastest Growing Segment INTERFERONS (IFNS) (Type)
    Forecast Period 2023-2028
    Growth Rate CAGR of 7.2% from 2023 to 2028
    Largest Segment PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES (End User)
    Market Size Base Year (Billions) ~USD 2.26 (2023)
    Revenue Forecast (Billions) ~USD 3.2 (2028)
    Segments Covered Product, Type, Application, Host Cell, End User

    Europe Recombinant Proteins Market Report Segmentation

    5 segment dimensions are covered across the global market.

    By Product

    • Adhesion Molecules & Receptors
    • Growth Factors & Chemokines
    • Immune Response Proteins
    • Kinase Proteins
    • Membrane Proteins
    • Other Recombinant Proteins
    • Recombinant Metabolic Enzymes
    • Regulatory Proteins
    • Structural Proteins

    By Type

    • Academic Research
    • Biologics
    • Biotechnology Research
    • Cell & Gene Therapy
    • Interferons (Ifns)
    • Interleukins (Ils)
    • Other Growth Factors & Chemokines
    • Vaccines

    By Application

    • Biopharmaceutical Production
    • Diagnostics
    • Drug Discovery & Development
    • Other Applications
    • Research

    By Host Cell

    • Bacterial Cells
    • Insect Cells
    • Mammalian Systems
    • Other Cell Hosts
    • Other Host Cells
    • Yeast & Fungi

    By End User

    • Academic Research Institutes
    • Biotechnology Companies
    • Contract Research Organizations
    • Other End Users
    • Pharmaceutical & Biopharmaceutical Companies

    REST OF EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028

    Segment20212022202320242025202620272028CAGR (%)
    ACADEMIC RESEARCH INSTITUTES26.727.328.229.430.832.334.135.95
    BIOTECHNOLOGY COMPANIES18.719.119.720.521.522.523.7254.8
    CONTRACT RESEARCH ORGANIZATIONS9.91010.310.711.211.712.312.94.6
    OTHER END USERS6.46.56.66.877.37.57.83.5
    PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES52.453.655.65860.863.967.571.35.1
    TOTAL114.11116.47120.44125.47131.23137.71145.09152.974.9

    EUROPE: RECOMBINANT PROTEINS MARKET, BY END USER, 2021–2028

    Segment20212022202320242025202620272028CAGR (%)
    ACADEMIC RESEARCH INSTITUTES124.5128.6135.4143.6153163.6175.7188.86.9
    BIOTECHNOLOGY COMPANIES87.490.294.8100.4106.8114122.3131.36.7
    CONTRACT RESEARCH ORGANIZATIONS4647.349.652.455.659.363.467.96.5
    OTHER END USERS29.53031.132.634.23638.140.35.3
    PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES244.7253.3267283.6302.6324348.5375.17
    TOTAL531.99549.41577.93612.64652.24696.92747.9803.416.8

    Target Audience

    • Pharmaceutical & Biotech Companies : Manufacturers and developers of recombinant proteins require detailed European market data to optimize product launches, identify expansion opportunities, and benchmark competitive positioning.
    • Healthcare Investors & Venture Capitalists : Investment firms need comprehensive market analysis to evaluate funding opportunities, assess portfolio company performance, and identify high-growth segments within Europe's recombinant proteins sector.
    • Contract Manufacturing Organizations (CMOs) : CMOs and contract development organizations require market intelligence to understand demand trends, capacity planning needs, and client requirements across European recombinant protein production.
    • Healthcare Policy & Regulatory Bodies : Government agencies and regulatory authorities use market data to inform healthcare policy, reimbursement strategies, and regulatory frameworks governing recombinant protein approvals in Europe.
    • Market Research & Consulting Firms : Research organizations and consultants leverage detailed European market insights to support client advisory services, competitive analysis, and strategic planning in the biopharmaceutical sector.

    Europe vs. other regions

    HowEurope compares to the other 3 regional blocs covered in this market.

    North America
    ~USD 1471.7 Million · 7.5% wtd CAGR ·
    Asia Pacific
    ~USD 744.5 Million · 7.8% wtd CAGR ·
    Latin America
    ~USD 91.4 Million · 5.5% wtd CAGR ·
    Middle East
    ~USD 28.6 Million · 2.3% wtd CAGR ·

    Countries within Europe - compare and drill down

    Country2025 size (native)
    GermanyUSD 10.6 Million
    United KingdomUSD 62.8 Million
    FranceUSD 6.5 Million
    ItalyUSD 2.7 Million
    SpainUSD 1.7 Million
    Rest Of EuropeUSD 54.9 Million

    Country market size visualization

    Germany
    USD 10.6 Million
    United Kingdom
    USD 62.8 Million
    France
    USD 6.5 Million
    Italy
    USD 2.7 Million
    Spain
    USD 1.7 Million
    Rest Of Europe
    USD 54.9 Million

    Reasons to Buy this Report

    • Regional Market Segmentation : Detailed breakdown of Europe's recombinant proteins market by country, including Germany, UK, France, Italy, and Spain, enabling targeted market entry and expansion strategies.
    • Competitive Landscape Analysis : Comprehensive insights into leading European biopharmaceutical companies, their market positioning, product portfolios, and strategic initiatives within the recombinant proteins sector.
    • Regulatory & Compliance Insights : In-depth understanding of EMA regulations, approval pathways, manufacturing standards, and compliance requirements specific to European recombinant protein commercialization.
    • Growth Opportunity Identification : Strategic analysis of emerging therapeutic areas, unmet medical needs, and market gaps across Europe where recombinant protein solutions can capture significant value.
    • Investment & Partnership Intelligence : Data-driven insights on funding trends, M&A activities, and collaboration opportunities among European biotech firms, enabling informed investment and partnership decisions.

    Frequently asked questions

    What is the current size of Europe's recombinant proteins market?

    Europe's recombinant proteins market was valued at $577.9 million in 2023 and is expected to grow to $803.4 million by 2028.

    What is the projected growth rate for recombinant proteins in Europe?

    Europe's recombinant proteins market is projected to grow at a compound annual growth rate (CAGR) of 6.8% from 2023 to 2028.

    Which therapeutic areas drive recombinant protein demand in Europe?

    Oncology, immunology, and rare disease segments are primary drivers of recombinant protein demand in Europe due to high unmet medical needs and advanced treatment protocols.

    How does Europe's regulatory environment support recombinant protein market growth?

    The European Medicines Agency (EMA) provides harmonized regulatory pathways that facilitate faster approval and commercialization of recombinant protein therapeutics across Europe.

    What role do contract manufacturers play in Europe's recombinant proteins market?

    Contract manufacturing organizations in Europe provide critical manufacturing, fill-finish, and quality assurance services that enable biopharmaceutical companies to scale recombinant protein production efficiently.

    RESEARCH METHODOLOGY

    This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global recombinant proteins market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.

    Secondary Research

    The secondary sources referred to for this research study include publications from government sources,such as the World Health Organization, The Antibody Society,Pharmaceutical Research and Manufacturers of America (PhRMA), National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC),National Center for Biotechnology Information (NCBI), American Medical Association (AMA), RecombinantAntibody Network (RAN), National Cancer Institute (NCI), Association of Medical Laboratory Immunologists (AMLI), American Society of Clinical Oncology (ASCO), United States Food & Drug Administration (US FDA), American Association for Cancer Research (AACR), Biomolecular Interaction Network Database, European Medicines Agency (EMA), British Society for Immunology (BSI), and the Institute for Molecular Medicine, corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, professional associations, and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

    Primary Research

    In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.

    Recombinant Protein Market 
 Size, and Share

    To know about the assumptions considered for the study, download the pdf brochure

    Market Size Estimation

    The top-down and bottom-up approaches were used to estimate & validate the total size of the recombinant proteins market. These methods were also used extensively to estimate the size of various market segments.

    Recombinant Protein Market Top Down and Bottom Up Approach

    Data Triangulation

    After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data were triangulated by analyzing various factors and trends from the demand and supply sides.

    Market Definition

    Recombinant proteins are manipulated proteins generated by recombinant DNA technology that modifies gene sequences. These are formed by transfecting foreign genes into a host cell. Recombinant proteins are primarily used to produce antibodies and enzymes for disease treatment, pharmaceutical products, protein-based polymers for drug delivery, and various other research & diagnostic uses. This market includes recombinant protein products, including growth factors, cytokines, recombinant enzymes, structural proteins, and membrane proteins.

    Key Stakeholders

    • Pharmaceutical & Biopharmaceutical Companies
    • Biotechnology Companies
    • Life Sciences Companies
    • Academic Research Institutes
    • Government Institutes
    • Private Research Firms
    • Contract Research Organizations (CROs)
    • Third-party Suppliers, Direct Suppliers, Distributors, and Channel Partners
    • Venture Capitalists and Investors
    • Market Research and Consulting Firms

    Report Objectives

    • To define, describe, and forecast the recombinant proteins market based on product, host cell, application, and end user
    • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
    • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall recombinant proteins market
    • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders  
    • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
    • To strategically profile the key players in the recombinant proteins market and comprehensively analyze their core competencies and market rankings
    • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the recombinant proteins market
    • To benchmark players within the recombinant proteins market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy

    Available customizations:

    With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

    Geographical Analysis

    • Further breakdown of the Rest of Europe recombinant proteins market, by country
    • Further breakdown of the Rest of Asia Pacific recombinant proteins market, by country
    • Further breakdown of the Rest of Latin America recombinant proteins market, by country

    Company Information

    • Detailed analysis and profiling of additional market players (up to five)

     

    Get the Full Recombinant Proteins Market Report

    Full forecast, segment splits, and company analysis for all Recombinant Proteins Market.

    Need a Tailored Report?

    Customize this report to your needs

    Get 10% FREE Customization

    Customize This Report
    Fact checked
    DMCA.com Protection Status